Cargando…
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550092/ https://www.ncbi.nlm.nih.gov/pubmed/36215283 http://dx.doi.org/10.1371/journal.pone.0276211 |
| _version_ | 1784805814959079424 |
|---|---|
| author | Shah, Manish A. Wainberg, Zev A. Catenacci, Daniel V. T. Hochster, Howard S. Ford, James Kunz, Pamela Lee, Fa-Chyi Kallender, Howard Cecchi, Fabiola Rabe, Daniel C. Keer, Harold Martin, Anne-Marie Liu, Yuan Gagnon, Robert Bonate, Peter Liu, Li Gilmer, Tona Bottaro, Donald P. |
| author_facet | Shah, Manish A. Wainberg, Zev A. Catenacci, Daniel V. T. Hochster, Howard S. Ford, James Kunz, Pamela Lee, Fa-Chyi Kallender, Howard Cecchi, Fabiola Rabe, Daniel C. Keer, Harold Martin, Anne-Marie Liu, Yuan Gagnon, Robert Bonate, Peter Liu, Li Gilmer, Tona Bottaro, Donald P. |
| author_sort | Shah, Manish A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9550092 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Public Library of Science |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95500922022-10-11 Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer Shah, Manish A. Wainberg, Zev A. Catenacci, Daniel V. T. Hochster, Howard S. Ford, James Kunz, Pamela Lee, Fa-Chyi Kallender, Howard Cecchi, Fabiola Rabe, Daniel C. Keer, Harold Martin, Anne-Marie Liu, Yuan Gagnon, Robert Bonate, Peter Liu, Li Gilmer, Tona Bottaro, Donald P. PLoS One Correction Public Library of Science 2022-10-10 /pmc/articles/PMC9550092/ /pubmed/36215283 http://dx.doi.org/10.1371/journal.pone.0276211 Text en © 2022 Shah et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction Shah, Manish A. Wainberg, Zev A. Catenacci, Daniel V. T. Hochster, Howard S. Ford, James Kunz, Pamela Lee, Fa-Chyi Kallender, Howard Cecchi, Fabiola Rabe, Daniel C. Keer, Harold Martin, Anne-Marie Liu, Yuan Gagnon, Robert Bonate, Peter Liu, Li Gilmer, Tona Bottaro, Donald P. Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer |
| title | Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer |
| title_full | Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer |
| title_fullStr | Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer |
| title_full_unstemmed | Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer |
| title_short | Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer |
| title_sort | correction: phase ii study evaluating 2 dosing schedules of oral foretinib (gsk1363089), cmet/vegfr2 inhibitor, in patients with metastatic gastric cancer |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550092/ https://www.ncbi.nlm.nih.gov/pubmed/36215283 http://dx.doi.org/10.1371/journal.pone.0276211 |
| work_keys_str_mv | AT shahmanisha correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT wainbergzeva correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT catenaccidanielvt correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT hochsterhowards correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT fordjames correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT kunzpamela correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT leefachyi correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT kallenderhoward correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT cecchifabiola correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT rabedanielc correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT keerharold correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT martinannemarie correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT liuyuan correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT gagnonrobert correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT bonatepeter correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT liuli correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT gilmertona correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer AT bottarodonaldp correctionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer |